• By Deanna Kamienski, Beth Allan, Amanda Micklus, Maureen Riordan, and Steven Muntner
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Tech Transfer Deals column provides a monthly update on technology transfer deals, reporting licensing agreements between companies and universities or other research institutions within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced August through September 2015.
Exiqon gets prostate cancer biomarkers from Aarhus Univ. Hosp.
Licensing a BTK inhibitor for progressive MS previously held by Biogen, Zenas says Phase III orelabrutinib can stave off disability related with disease progression.
Chiesi and the Boston-area biotech will co-develop a CRISPR-Cas gene-editing therapy for primary hyperoxaluria type 1. They hope to provide a curative therapy for the rare disease.
With 52-week Phase II data, struggling Biomea said it would go forward in insulin-deficient type 2 diabetes patients and those who had not achieved HbA1c goals on GLP-1 therapy.
